Zatosetron

LY 191617, LY 277359

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Franz PM, Mattiuz EL, Rubin A, et al. Disposition of [14C]-zatosetron, a selective and potent serotonin receptor (5HT3) antagonist, in healthy men after oral administration. FASEB J 1992 Feb 26; 6: A1570
Google Scholar
Chappell AS, Bay JM, Botzum GD, et al. Zatosetron, a 5-HT(3) receptor antagonist in a multicenter trial for acute migraine. Neuropharmacology 1994 Mar-Apr; 33: 509–13
Article PubMed CAS Google Scholar
Smith WT, Londborg PD, Blomgren SL, et al. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol 1999 Apr; 19: 125–31
Article PubMed CAS Google Scholar
Cohen ML, Bloomquist W, Schmid CR, et al. Zatosetron, a selective 5-HT3 receptor antagonist: pharmacological activities of human and animal metabolites. Drug Dev Res 1993 Jul; 29: 209–15
Article CAS Google Scholar
Williams PD, Calligaro DO, Colbert WE, et al. General pharmacology of a new potent 5-hydroxytryptamine antagonist. Arzneimittel Forschung 1991 Mar; 41: 189–95
PubMed CAS Google Scholar
Schwartz SM, Goldberg MJ, Gidda JS, et al. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men. J Clin Pharmacol 1994 Mar; 34: 250–4
PubMed CAS Google Scholar

Zatosetron. Drugs R&D 2, 253–255 (1999). https://doi.org/10.2165/00126839-199902040-00009

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.